287 related articles for article (PubMed ID: 28351581)
1. Characterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancer.
Chan OS; Kowanetz M; Ng WT; Koeppen H; Chan LK; Yeung RM; Wu H; Amler L; Mancao C
Oral Oncol; 2017 Apr; 67():52-60. PubMed ID: 28351581
[TBL] [Abstract][Full Text] [Related]
2. Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma.
Zhang J; Fang W; Qin T; Yang Y; Hong S; Liang W; Ma Y; Zhao H; Huang Y; Xue C; Huang P; Hu Z; Zhao Y; Zhang L
Med Oncol; 2015 Mar; 32(3):86. PubMed ID: 25702326
[TBL] [Abstract][Full Text] [Related]
3. Correlation of PD-L1 Expression of Tumor Cells with Survival Outcomes after Radical Intensity-Modulated Radiation Therapy for Non-Metastatic Nasopharyngeal Carcinoma.
Lee VH; Lo AW; Leung CY; Shek WH; Kwong DL; Lam KO; Tong CC; Sze CK; Leung TW
PLoS One; 2016; 11(6):e0157969. PubMed ID: 27341634
[TBL] [Abstract][Full Text] [Related]
4. Characterization of PD-L1 and PD-1 Expression and CD8+ Tumor-infiltrating Lymphocyte in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
Larbcharoensub N; Mahaprom K; Jiarpinitnun C; Trachu N; Tubthong N; Pattaranutaporn P; Sirachainan E; Ngamphaiboon N
Am J Clin Oncol; 2018 Dec; 41(12):1204-1210. PubMed ID: 29672367
[TBL] [Abstract][Full Text] [Related]
5. PD-1 high expression predicts lower local disease control in stage IV M0 nasopharyngeal carcinoma.
Jiang F; Yu W; Zeng F; Cheng G; Xu J; Yang S; Shui Y; Wu D; Yu XF; Wei Q
BMC Cancer; 2019 May; 19(1):503. PubMed ID: 31138162
[TBL] [Abstract][Full Text] [Related]
6. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
7. CD3+T-lymphocyte infiltration is an independent prognostic factor for advanced nasopharyngeal carcinoma.
Al-Rajhi N; Soudy H; Ahmed SA; Elhassan T; Mohammed SF; Khoja HA; Ghebeh H
BMC Cancer; 2020 Mar; 20(1):240. PubMed ID: 32199452
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load.
Zhou Y; Shi D; Miao J; Wu H; Chen J; Zhou X; Hu D; Zhao C; Deng W; Xie C
Sci Rep; 2017 Mar; 7():43627. PubMed ID: 28256540
[TBL] [Abstract][Full Text] [Related]
9. Expression of Immune Checkpoint Regulators, Cytotoxic T-Lymphocyte Antigen-4, and Programmed Death-Ligand 1 in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
Ahmed MM; Gebriel MG; Morad EA; Saber IM; Elwan A; Salah M; Fakhr AE; Shalaby AM; Alabiad MA
Appl Immunohistochem Mol Morphol; 2021 Jul; 29(6):401-408. PubMed ID: 33480605
[TBL] [Abstract][Full Text] [Related]
10. Prognostic stratification of patients with nasopharyngeal carcinoma based on tumor immune microenvironment.
Ono T; Azuma K; Kawahara A; Sasada T; Matsuo N; Kakuma T; Kamimura H; Maeda R; Hattori C; On K; Nagata K; Sato F; Chitose SI; Shin B; Aso T; Akiba J; Umeno H
Head Neck; 2018 Sep; 40(9):2007-2019. PubMed ID: 29756253
[TBL] [Abstract][Full Text] [Related]
11. Programmed Death-Ligand 1 Expression, Microsatellite Instability, Epstein-Barr Virus, and Human Papillomavirus in Nasopharyngeal Carcinomas of Patients from the Philippines.
Chang AMV; Chiosea SI; Altman A; Pagdanganan HA; Ma C
Head Neck Pathol; 2017 Jun; 11(2):203-211. PubMed ID: 27807760
[TBL] [Abstract][Full Text] [Related]
12. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma.
Thompson ED; Zahurak M; Murphy A; Cornish T; Cuka N; Abdelfatah E; Yang S; Duncan M; Ahuja N; Taube JM; Anders RA; Kelly RJ
Gut; 2017 May; 66(5):794-801. PubMed ID: 26801886
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors.
Wang H; Li Z; Dong B; Sun W; Yang X; Liu R; Zhou L; Huang X; Jia L; Lin D
Diagn Pathol; 2018 May; 13(1):30. PubMed ID: 29789013
[TBL] [Abstract][Full Text] [Related]
14. Expression and clinical significance of PD-L1 and BRAF expression in nasopharyngeal carcinoma.
Cao Y; Chan KI; Xiao G; Chen Y; Qiu X; Hao H; Mak SC; Lin T
BMC Cancer; 2019 Oct; 19(1):1022. PubMed ID: 31664962
[TBL] [Abstract][Full Text] [Related]
15. Nasopharyngeal cancer cell-derived exosomal PD-L1 inhibits CD8+ T-cell activity and promotes immune escape.
Yang J; Chen J; Liang H; Yu Y
Cancer Sci; 2022 Sep; 113(9):3044-3054. PubMed ID: 35598173
[TBL] [Abstract][Full Text] [Related]
16. The Prognostic Significance of APOBEC3B and PD-L1/PD-1 in Nasopharyngeal Carcinoma.
Feng C; Zhang Y; Huang J; Zheng Q; Yang Y; Xu B
Appl Immunohistochem Mol Morphol; 2021 Mar; 29(3):239-244. PubMed ID: 32205739
[TBL] [Abstract][Full Text] [Related]
17. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.
Hsu C; Lee SH; Ejadi S; Even C; Cohen RB; Le Tourneau C; Mehnert JM; Algazi A; van Brummelen EMJ; Saraf S; Thanigaimani P; Cheng JD; Hansen AR
J Clin Oncol; 2017 Dec; 35(36):4050-4056. PubMed ID: 28837405
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients.
Kim HR; Ha SJ; Hong MH; Heo SJ; Koh YW; Choi EC; Kim EK; Pyo KH; Jung I; Seo D; Choi J; Cho BC; Yoon SO
Sci Rep; 2016 Nov; 6():36956. PubMed ID: 27841362
[TBL] [Abstract][Full Text] [Related]
19. Good prognostic factor in patients with nonmetastatic nasopharyngeal carcinoma: Programmed death ligand-1 expression in tumor cells.
Sahinli H; Akyürek N; Yılmaz M; Kandemir O; Duran AO; Kulaçoǧlu S; Uçar G; Acar E; Özet A; Öksüzoǧlu OBÇ; Özdemir NY
J Cancer Res Ther; 2020 Dec; 16(Supplement):S43-S47. PubMed ID: 33380650
[TBL] [Abstract][Full Text] [Related]
20. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
[No Abstract] [Full Text] [Related]
[Next] [New Search]
